Calcimmimetics can improve the calcium sensitivity of parathyroid calcium-sensitive receptors and reduce calcium, phosphorus, and PTH levels [185], not only to control secondary hyperparathyroidism in patients with CKD, but also to improve vascular calcification and maintain normal bone metabolism. The gene discussed is PTH; the disease is chronic kidney disease.